Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25184167 | 1.00 | CRBN (0.58) | CRBNDDB1GPR119NAMPTKDM4E | |
| SCHEMBL31127612 | 0.92 | CRBN (0.57) | CRBNDDB1GPR119NAMPTKDM4E | |
| SCHEMBL25187964 | 0.91 | CRBN (0.67) | CRBNDDB1GPR119NAMPTKDM4E | |
| SCHEMBL23301622 | 0.91 | CRBN (0.67) | CRBNDDB1GPR119NAMPTKDM4E | |
| SCHEMBL24206650 | 0.91 | CRBN (0.67) | CRBNDDB1GPR119NAMPTKDM4E | |
| SCHEMBL24670555 | 0.89 | DDB1 (0.58) | CRBNDDB1GPR119MAPTBACE1 | |
| SCHEMBL24480896 | 0.88 | DDB1 (0.54) | CRBNDDB1GPR119 | |
| SCHEMBL27178787 | 0.87 | DDB1 (0.66) | CRBNDDB1GPR119NAMPTMAPT | |
| SCHEMBL24671838 | 0.87 | DDB1 (0.58) | CRBNDDB1GPR119MAPT | |
| SCHEMBL24670627 | 0.87 | DDB1 (0.58) | CRBNDDB1GPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | CRBN 37/4885DDB1 353/4885GPR119 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.